The Management of Isolated Renal Recurrence of Renal Cell Carcinoma Following Complete Response to Interleukin-2 Based Immunotherapy

Long, J. P.; Walther, McClellan M.; Alexander, Richard B.; Linehan, W. Marston; Rosenberg, Steven A.

doi:10.1016/s0022-5347(17)35428-9

Cited by 9 publications

(3 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Des weiteren besteht die Möglichkeit, durch vorherige Immunmodulation die Voraussetzungen für einen metastasenchirurgischen Eingriff zu verbessern, wie in einigen Studien dargelegt wurde [7,12,22,23]. Ob die Exzision von Metastasen eines Nierenzellkarzinoms die Ergebnisse einer nachfolgenden Immunmodulation verbessert, können nur randomisierte, prospektive Studien zeigen.…”

Section: Introductionunclassified

Surgical treatment of metastases in patients with renal cell carcinoma

et al. 1997

View full text Add to dashboard Cite

The aim of the present study was to investigate the efficacy of surgical excision of metastases in patients with renal cell carcinoma (RCC). Eighteen patients with metastatic RCC underwent resection of metastases between 1988 and 1994 (pulmonary: n = 6; skeletal: n = 6; cerebral: n = 3; local relapse: n = 3). Two patients suffered from synchronous appearance of metastases, whereas in 16 cases a metachronous occurrence was observed. In 12 out of a total of 18 patients metastases were completely resected. These patients survived longer than patients in whom metastases were incompletely resected (30 vs. 12 months). Six out of these 12 patients with a complete resection of metastases are presently free of disease for a mean duration of 24 months (10-34 months). The resection of lung metastases seems to be associated with longer survival times. In conclusion, surgical resection of metastases--solitary or single organ site--especially in the lung appears to be justified in patients with RCC. The surgical excision of skeletal metastases at least improves quality of life.

show abstract

Section: Introductionunclassified

Surgical treatment of metastases in patients with renal cell carcinoma

et al. 1997

View full text Add to dashboard Cite

show abstract

“…reported on two patients who had metachronous tumors in a solitary kidney after immunotherapy; both of them were tumor free for at least 11 months. [ 24 ] In 1996, Krishnamurthi et al . retrospectively reviewed 15 patients who underwent NSS for MRCC because of a solitary kidney or CKD secondary to hypertension or diabetes mellitus.…”

Section: Discussionmentioning

confidence: 99%

Partial nephrectomy for metastatic renal cell carcinoma: Where do we stand?

2015

View full text Add to dashboard Cite

Nephron-sparing surgery (NSS) for renal cell carcinoma (RCC) offers comparable oncologic results, but a lower risk of chronic kidney disease, when compared with radical nephrectomy. However, there are limited data in the literature examining the safety of NSS in the setting of metastatic RCC. To evaluate the feasibility of NSS and impact on cancer-specific survival (CSS) in patients with metastatic disease, we performed a systematic review of the literature. There is ample evidence that NSS is feasible in metastatic RCC, with comparable results in terms of CSS compared with radical cytoreductive nephrectomy.

show abstract

“…Spontaneous regression and response to immunotherapy are two unique characteristics of RCC [9, 10, 11, 12]which suggest that immune surveillance may be involved in the regression of this tumor. We used molecular techniques to investigate the relationships between HLA-DR antigens/alleles and RCC in Japanese patients.…”

Section: Introductionmentioning

confidence: 99%

HLA-DRB Genotypes in Japanese Patients with Renal Cell Carcinoma

et al. 2000

View full text Add to dashboard Cite

Objectives: Several clinical features, such as the spontaneous regression of some renal cell carcinoma (RCC) metastases after nephrectomy, suggest immune involvement in tumor destruction. Patients and Methods: We investigated the role of genetic variation at the HLA class II loci in RCC by analyzing the HLA-DR antigen and HLA-DRB1, DRB3, DRB4 and DRB5 alleles in 55 patients using the polymerase chain rection. Results: No statistically significant differences were observed in the frequency of the HLA-DR antigen or HLA-DRB3, DRB4, or DRB5 genes between the patients and a healthy control group. On the other hand, the HLA-DRB1*0403 and *1202 alleles were significantly more frequent in the patients than in the controls (p < 0.001 and p < 0.01, respectively). Conclusion: RCC might be linked to these two alleles in Japanese patients.

show abstract

The Management of Isolated Renal Recurrence of Renal Cell Carcinoma Following Complete Response to Interleukin-2 Based Immunotherapy

Cited by 9 publications

References 17 publications

Surgical treatment of metastases in patients with renal cell carcinoma

Surgical treatment of metastases in patients with renal cell carcinoma

Partial nephrectomy for metastatic renal cell carcinoma: Where do we stand?

HLA-DRB Genotypes in Japanese Patients with Renal Cell Carcinoma

Contact Info

Product

Resources

About